Wolverine: Two Mechanisms, No Combination Study

The short version

Wolverine is a research-community two-peptide blend pairing BPC-157 (Body Protection Compound 157, a 15-amino-acid gastric peptide) with TB-500 (Ac-LKKTETQ, the actin-binding fragment of thymosin beta-4). The mechanistic rationale is that BPC-157 supplies a local cytoprotective and pro-angiogenic signal via VEGFR2 ^[10], while TB-500 supplies an intracellular actin-sequestration signal that underlies cell migration, re-epithelialization and progenitor mobilization ^[11]. Two different pathways, one described as complementary.

The operative constraint: no peer-reviewed study has been published that defines a synergy ratio, dose or endpoint for these two peptides given together ^[8]. A 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only 1 human, "no clinical safety data" — makes no mention of TB-500 or combination use ^[8]. Both constituents are unapproved; both are WADA-prohibited. This page reports the component evidence and the blend's documented limitations. It does not recommend a dose or a use.

What it is

Wolverine is not a single chemical entity. It is a co-formulated pairing of two distinct synthetic peptides.

BPC-157: a 15-amino-acid pentadecapeptide with sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (C62H98N16O22, ~1419.5 Da), derived from a partial sequence of Body Protection Compound found in human gastric juice.

TB-500: a synthetic N-acetylated heptapeptide, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ; C38H68N10O14, ~889.0 Da), corresponding to residues 17-23 — the actin-binding motif — of the endogenous 43-residue protein Thymosin Beta-4 (Tβ4, ~4963 Da).

The blend has no single molecular weight, CAS number or structure; the values above describe the two constituents individually. Fixed-ratio research vials typically combine equal masses of each component.

How it works

The Wolverine blend is rationalized as a two-mechanism pairing.

BPC-157 supplies a local cytoprotective and pro-angiogenic signal: it upregulates and internalizes the VEGFR2 receptor, switching on the VEGFR2-Akt-eNOS pathway downstream, which drives new vessel formation and accelerates blood-flow recovery in ischemic muscle ^[10]. Additional reported routes include FAK-paxillin (cell migration) and growth-hormone-receptor sensitization in tendon fibroblasts.

TB-500 (and more robustly, full-length thymosin beta-4) supplies an intracellular actin-sequestration signal: the LKKTETQ motif binds monomeric G-actin 1:1, capping both ends of the monomer and regulating the pool of unpolymerized actin that governs cytoskeletal dynamics, cell migration and wound-closure kinetics ^[11]. In injury models, Tβ4 is associated with accelerated cell migration, angiogenesis, anti-inflammatory and anti-apoptotic signaling, and reduced scar-forming myofibroblast activity ^[11].

The synergy argument is that angiogenesis (BPC-157) and cell migration (TB-500/Tβ4) are largely non-overlapping steps of the same repair cascade. The synergy claim is a theoretical extrapolation — no controlled head-to-head or combination study has defined a synergistic dose, ratio or endpoint for these two peptides given together.

What the research shows

Regulatory and safety framing. A 2026 Sports Medicine narrative review covering BPC-157 and TB-500/thymosin beta-4 among unapproved musculoskeletal peptides concluded that many such peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, the potential for serious harm exists, and these compounds operate largely outside regulatory oversight ^[1].

Evidence gap for the combination. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies — 35 preclinical, only 1 human — found "no clinical safety data," and concluded evidence is level IV-V (lowest tiers). It makes no mention of TB-500 or any combination; this absence is itself evidence that no controlled Wolverine combination study exists ^[8].

Human evidence for BPC-157. A 2025 narrative review states that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and recommends treating it as investigational ^[9].

BPC-157 angiogenesis mechanism. BPC-157 upregulates VEGFR2 expression and promotes VEGFR2 internalization with downstream VEGFR2-Akt-eNOS pathway activation, increasing vessel density in chick membrane and rat hindlimb ischemia models and accelerating blood-flow recovery; effects were blocked by endocytosis inhibition ^[10].

Thymosin beta-4 mechanism. A multi-model review consolidated thymosin beta-4's actin-binding, pro-migratory, anti-scarring, anti-inflammatory and angiogenic activities as the rationale for clinical development in dermal wounds, corneal injury, and heart and CNS repair ^[11]. Note: this literature addresses full-length Tβ4, not the TB-500 fragment.

Reported effects, cautions & safety

No community-anecdote signals are compiled in this desk's source material for the Wolverine blend specifically. The following cautions come from the cited literature.

• No controlled combination study. No peer-reviewed study has defined a synergy ratio, dose or endpoint for BPC-157 and TB-500 given together. The 2025 HSS Journal systematic review of BPC-157 (36 studies, 1 human, "no clinical safety data") makes no mention of TB-500 or combination use ^[8].
• TB-500 identity caveat. "TB-500" as sold is the Ac-LKKTETQ heptapeptide (~889 Da), but the overwhelming majority of efficacy data attributed to it were generated with full-length thymosin beta-4 (~4963 Da) ^[8]. Wolverine marketing borrows full-length Tβ4 data for one of its two components.
• Preclinical-dominant evidence. BPC-157 has only three small human pilots; the TB-500 fragment has zero completed controlled human trials (human Tβ4 data are for the full-length protein). The combination's human efficacy and safety are entirely unproven ^[8][9].
• Tumor / angiogenesis signal. Thymosin beta-4 is overexpressed in several cancers and implicated in tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression — a concern compounded when two pro-repair peptides are combined ^[11].
• WADA prohibition. Both BPC-157 (S0, non-approved substances) and TB-500/thymosin beta-4 (S2, peptide hormones/growth factors) are prohibited by the World Anti-Doping Agency, banned in and out of competition ^[1][8].
• Non-regulated supply. Both constituents are distributed through non-regulated channels; product identity, purity and the actual ratio are unverified outside formal studies.

Where it fits in recovery research

Among the four entries on this desk, Wolverine sits between the full four-component KLOW blend and the two standalone singles. Its two-mechanism rationale — angiogenesis plus cell migration — is arguably the tightest mechanistic argument for combining peptides on this desk, but it still lacks any controlled combination evidence ^[8]. BPC-157 and TB-500 each have their own pages covering the single-component literature in more depth. See the comparison page for how all four line up.